Ethnopharmacology & Physiotherapy Congress 2019: Comparison Of The Antineoplastic Activity Of The Free Cannabis Sativa L Extracts And Cannabidiol (Cbd) - Ervin Ivanov - German Cancer Research Centre

Author(s): Ervin Ivanov

Abstract

Background: The unfavorable side-effect profiles of most chemotherapeutics create incentive toward finding active substances with less toxicity. We compared the anti-neoplastic activity of different botanical substances (BDS) from Cannabis Sativa L (hemp) made using different manufacturing technologies by PBG Global in lymphoma, mammary gland adenocarcinoma and urinary bladder cancer. We also aimed to determine the benefits of different Cannabis Sativa L extracts compared to pure CBD reference in normalized doses.

Materials & methods: Cytotoxicity was measured by the MTT assay. Used preparations - BDS#1 THC-free 30% CBD Cannabis Sativa L extract (Hemp), BDS#2 THC-free 60% CBD hemp extract, BDS#3 99% CBD isolate, all produced by PBG Global and BDS#4 99% CBD isolate analytical standard as reference compound was sourced from Sigma-Aldrich. We used following cell lines: T-24 (urinary bladder transitional cell carcinoma), MDA-MB-231 (mammary gland adenocarcinoma), HuT-78 (Sézary syndrome CTCL), and MJ (mycosis fungoides CTCL)

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.